JP2025529240A - トリナパント、セダズリジン及びデシタビンによるｔ細胞リンパ腫の治療のための併用療法 - Google Patents

トリナパント、セダズリジン及びデシタビンによるｔ細胞リンパ腫の治療のための併用療法

Info

Publication number
JP2025529240A
JP2025529240A JP2025513127A JP2025513127A JP2025529240A JP 2025529240 A JP2025529240 A JP 2025529240A JP 2025513127 A JP2025513127 A JP 2025513127A JP 2025513127 A JP2025513127 A JP 2025513127A JP 2025529240 A JP2025529240 A JP 2025529240A
Authority
JP
Japan
Prior art keywords
cell lymphoma
decitabine
trinapant
lymphoma
composition
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2025513127A
Other languages
English (en)
Japanese (ja)
Other versions
JP2025529240A5 (https=
Inventor
ジョン シムズ，マーティン
アルバート ウォード，ジョージ
キール，ハロルド
オガネシアン，アラム
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Taiho Pharmaceutical Co Ltd
Original Assignee
Taiho Pharmaceutical Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Taiho Pharmaceutical Co Ltd filed Critical Taiho Pharmaceutical Co Ltd
Publication of JP2025529240A publication Critical patent/JP2025529240A/ja
Publication of JP2025529240A5 publication Critical patent/JP2025529240A5/ja
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
    • A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
    • A61K31/7068—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
    • A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
    • A61K31/7068—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid
    • A61K31/7072—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid having two oxo groups directly attached to the pyrimidine ring, e.g. uridine, uridylic acid, thymidine, zidovudine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Molecular Biology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
JP2025513127A 2022-08-31 2022-11-04 トリナパント、セダズリジン及びデシタビンによるｔ細胞リンパ腫の治療のための併用療法 Pending JP2025529240A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US202263374137P 2022-08-31 2022-08-31
US63/374,137 2022-08-31
PCT/IB2022/060652 WO2024047394A1 (en) 2022-08-31 2022-11-04 Combination therapies for treatment of t-cell lymphomas with tolinapant, cedazuridine and decitabine

Publications (2)

Publication Number Publication Date
JP2025529240A true JP2025529240A (ja) 2025-09-04
JP2025529240A5 JP2025529240A5 (https=) 2025-11-05

Family

ID=84359488

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2025513127A Pending JP2025529240A (ja) 2022-08-31 2022-11-04 トリナパント、セダズリジン及びデシタビンによるｔ細胞リンパ腫の治療のための併用療法

Country Status (9)

Country Link
US (1) US20240082286A1 (https=)
EP (1) EP4580635A1 (https=)
JP (1) JP2025529240A (https=)
KR (1) KR20250053870A (https=)
AU (1) AU2022476674A1 (https=)
CA (1) CA3266274A1 (https=)
MX (1) MX2025002312A (https=)
TW (1) TW202410893A (https=)
WO (1) WO2024047394A1 (https=)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BR122022015241B1 (pt) 2013-12-20 2023-09-26 Astex Therapeutics Limited Compostos heterocíclicos bicíclicos intermediários para a preparação de um composto de fórmula (i)

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3845770A (en) 1972-06-05 1974-11-05 Alza Corp Osmatic dispensing device for releasing beneficial agent
US4326525A (en) 1980-10-14 1982-04-27 Alza Corporation Osmotic device that improves delivery properties of agent in situ
US5364620A (en) 1983-12-22 1994-11-15 Elan Corporation, Plc Controlled absorption diltiazem formulation for once daily administration
US5023252A (en) 1985-12-04 1991-06-11 Conrex Pharmaceutical Corporation Transdermal and trans-membrane delivery of drugs
US5001139A (en) 1987-06-12 1991-03-19 American Cyanamid Company Enchancers for the transdermal flux of nivadipine
US4992445A (en) 1987-06-12 1991-02-12 American Cyanamid Co. Transdermal delivery of pharmaceuticals
US4902514A (en) 1988-07-21 1990-02-20 Alza Corporation Dosage form for administering nilvadipine for treating cardiovascular symptoms
JO2778B1 (en) 2007-10-16 2014-03-15 ايساي انك Certain Compounds, Compositions and Methods
BR122022015241B1 (pt) 2013-12-20 2023-09-26 Astex Therapeutics Limited Compostos heterocíclicos bicíclicos intermediários para a preparação de um composto de fórmula (i)
US12239653B2 (en) * 2020-02-25 2025-03-04 Taiho Pharmaceutical Co., Ltd. Combination decitabine and cedazuridine solid oral dosage forms

Also Published As

Publication number Publication date
TW202410893A (zh) 2024-03-16
US20240082286A1 (en) 2024-03-14
WO2024047394A1 (en) 2024-03-07
CA3266274A1 (en) 2024-03-07
KR20250053870A (ko) 2025-04-22
AU2022476674A1 (en) 2025-04-17
MX2025002312A (es) 2025-04-02
EP4580635A1 (en) 2025-07-09

Similar Documents

Publication Publication Date Title
US11672800B2 (en) Combination therapies with EHMT2 inhibitors
US10537580B2 (en) Azocane and azonane derivatives and methods of treating hepatitis B infections
JP7691494B2 (ja) 架橋三環式カルバモイルピリドン化合物及びその使用
WO2019133712A1 (en) Combined modalities for nucleosides and/or nadph oxidase (nox) inhibitors as myeloid-specific antiviral agents
US11149011B2 (en) Compounds and methods for IDO and TDO modulation, and indications therefor
CN101983062A (zh) 提高abca-1的化合物及其用途
JP2017531619A5 (https=)
EP2906564B1 (en) Treating brain cancer using agelastatin a (aa) and analogues thereof
US20240165116A1 (en) Rock2 inhibitor for the treatment of viral infection
CN107108557A (zh) 用于治疗和预防呼吸道合胞体病毒(rsv)感染的螺环二氢吲哚类
WO2022256529A1 (en) Compounds for treating nash and nafld
TWI857018B (zh) 2'3'-環二核苷酸及其前藥
JP2025529240A (ja) トリナパント、セダズリジン及びデシタビンによるｔ細胞リンパ腫の治療のための併用療法
US20210369715A1 (en) Novel uses
US20250186451A1 (en) Methods of treating cancer with iap antagonist compounds and combination therapies
US11572362B2 (en) Pyrrolo[1,2-b]pyridazine derivatives
US20200048261A1 (en) PYRROLO[1,2-b]PYRIDAZINE DERIVATIVES
EP3720440A1 (en) Treatment of rsv with combination product
HK40092944B (zh) 桥连三环氨基甲酰基吡啶酮化合物及其用途
HK40092944A (zh) 桥连三环氨基甲酰基吡啶酮化合物及其用途
US20240041854A1 (en) Cold medicine and antiviral medicine
JP2023139233A5 (https=)
HK40129600A (zh) 用於治疗病毒感染的4-氨基吡咯并[2，1-f][1，2，4]三嗪c-核苷化合物和方法
CN120112288A (zh) 用于治疗肿瘤的药物组合、药物组合物及其用途
HK40057712B (zh) 含有n杂五元环的衣壳蛋白装配抑制剂、其药物组合物和用途

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20251024

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20251024